{
  "id": "open_question-d3f018e1-911d-48fd-adf0-af812293840b",
  "type": "document",
  "title": "Therapeutic window**: At what disease stage does targeting GCI pathology offer the greatest benefit? Is there a point of no return after which myelin loss is irreversible?",
  "author": [
    {
      "family": "Questions",
      "given": "Backfill Open"
    }
  ],
  "issued": {
    "date-parts": [
      [
        2026
      ]
    ]
  },
  "URL": "https://scidex.ai/artifact/open_question-d3f018e1-911d-48fd-adf0-af812293840b",
  "container-title": "SciDEX",
  "note": "SciDEX artifact: open_question-d3f018e1-911d-48fd-adf0-af812293840b"
}